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ABSTRACT
Research on healthy aging in men has increasingly focused on age-related 
hormonal changes. Testosterone (T) decline is primarily investigated, while age-
related changes in other sex steroids (dehydroepiandrosterone [DHEA], estradiol 
[E2], progesterone [P]) are mostly neglected. An integrated hormone parameter 
reflecting aging processes in men has yet to be identified. 271 self-reporting healthy 
men between 40 and 75 provided both psychometric data and saliva samples for 
hormone analysis. Correlation analysis between age and sex steroids revealed 
negative associations for the four sex steroids (T, DHEA, E2, and P). Principal 
component analysis including ten salivary analytes identified a principal component 
mainly unifying the variance of the four sex steroid hormones. Subsequent principal 
component analysis including the four sex steroids extracted the principal component 
of declining steroid hormones (DSH). Moderation analysis of the association between 
age and DSH revealed significant moderation effects for psychosocial factors such 
as depression, chronic stress and perceived general health. In conclusion, these 
results provide further evidence that sex steroids decline in aging men and that the 
integrated hormone parameter DSH and its rate of change can be used as biomarkers 
for healthy aging in men. Furthermore, the negative association of age and DSH is 
moderated by psychosocial factors.
INTRODUCTION
Aging, per se, dramatically increases the 
vulnerability to pathology and disease [1-4]. The current 
demographic shift towards a significantly older population 
is leading to an unprecedented rise of disability and 
dependence in our society. Health care costs are expected 
to rise enormously [5, 6]. Therefore, one of the most 
crucial health care goals for the upcoming decades is to 
prolong health span and delay aging itself [7]. To achieve 
this goal, new strategies and methods are required to 
prevent unhealthy aging already in early adulthood. 
Dysfunctional aging-patterns need to be identified and 
high sensitivity to maladaptive changes has to be provided, 
so that signs of declining health may be easily detected 
and successfully addressed [7, 8].
Over the last 25 years, research on healthy aging 
in men has increasingly focused on age-related hormonal 
changes starting around the age of 40. In the aging male, 
the decline in free testosterone (fT) of 2-3% per year 
has been linked to age-related clinical conditions such 
as frailty, erectile dysfunction, or depression [9, 10]. 
The syndrome of late-onset hypogonadism (LOH) has 
been defined as serum fT levels below 220 pmol/l and 
the presence of at least three sexual symptoms such as 
erectile dysfunction or low sexual desire [9]. The overall 
prevalence of LOH in the European Male Aging Study, 
which included 3369 men aged 40 to 79 years, was 2.1%; 
the number was significantly higher for the age groups 60 
to 69 years (3.2%) and 70 to 79 years (5.1%) [9].
Recent studies show similar importance of low levels 
of dehydroepiandrosterone (DHEA), estradiol (E2), and 
progesterone (P) for different areas of life (psychological, 
sexual, cognitive, and physical functioning) within the 
aging men 11-13]. Still, low testosterone (T) levels are 
mostly the solely target of therapeutic treatments in 
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Table 2: Descriptive statistics of sex steroids (pg/mL) and the principal component of declining steroid hormones 
(DSH)
Testosterone (T) Dehydroepiandrosterone (DHEA)
Estradiol 
(E2) Progesterone (P)
Principal 
component 
(DSH)
Na 268 266 270 264 256
Mean (SD) 67.37 (26.72) 256.25 (224.26) 1.32 (.99) 28.43 (18.79) -.12 (.94)
Minimum 7.77 8.07 .16 .05 -1.54
Maximum 165.06 1129.51 6.0 104.18 3.98
aAbsolute number of analyzed hormonal parameter included for statistical analyses. For extraction of DSH a principal 
component analysis with T, DHEA, E2 and P was performed. Only participants that provided saliva samples and their samples 
were not contaminated or values for T, DHEA, E2 or P were not below the detection limit or identified as outliers provided 
data for the computation of DSH (N = 256).
Table 1: Characteristics of the sample
Total N = 271 % = 100
Age (Mean / SD) 57.1 10.7
Current health condition (N / %):
Very good 97 35.8
Good 148 54.6
Fair 26 9.6
Bad
Very bad
0 
0 
0.0
0.0
Body mass index (kg/m2) (Mean / SD) 25.4 3.4
Education (N / %): 
tertiary education 106 39.1
post secondary non-tertiary education 57 21.0
Higher secondary school 76 28.0
Lower secondary education
Did not finish regular school
32
2
11.1
0.8
Current smoking status (N / %):
Non smoker
Occasional smoker
Smoker
224
25
22
82.7
9.1
8.2
Medication intake (N / %):
No
Yes
Medication type useda (N / %):
Antihypertensives
Antidepressants
Anti-inflammatory or painkiller
Others
180
91
40
7
28
49
66.4
33.6
14.8
2.6
10.3
18.1
aParticipants could indicate to use more than one medication simultaneously.
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relation to LOH while the clinical relevance of low levels 
of DHEA, E2, or P generally tends to be neglected [14]. 
Due to the strong interrelation between steroid hormones, 
the single assessment of one steroid hormone only seems 
to be insufficient to adequately reflect the hormonal state 
of an individual. For example, a hormonal imbalance 
could be expressed by high T levels while the expression 
of DHEA and P are below a critical range. Therefore, 
examining only a single hormone may lead to wrong 
interpretations in some cases [15, 16].
Due to large inter-individual differences in hormone 
concentrations agreement on norm values for circulating 
blood or saliva levels is still missing. While literature 
generally agrees on age-dependent progressive decline of 
free T, DHEA, and E2 [17-19], conflicting data on age-
related free P-decline in men is reported [20, 21]. It has 
become clear, however, that not only age-related changes 
in T, but also in DHEA, E2, and potentially also in P, are 
responsible for a variety of diseases met by aging men 
such as dementia, frailty, depression, or sexual dysfunction 
[22-25].
Therefore, the rate of change in declining steroid 
hormones seems to be a robust parameter of health 
deterioration. Higher endogenous levels of T, DHEA, 
E2, and P in older men are related to better mental and 
physical health and a slower decline of these steroids with 
age is regarded as health protective [26, 27]. In addition, 
apparent and self-reported good health have been shown 
to be associated with attenuated age-related sex steroid 
decline in men [17, 28]. In line with these findings, a 
follow up examination after four years of men aged 40 to 
79 showed weight gain of more than 10% to be associated 
with a greater decline in T [29]. To our knowledge, no 
psychosocial factors have been associated with reduced or 
increased age-related sex steroid decline in men to date.
The primary aim of the present study was to identify 
a comprehensive biological indicator of healthy aging in 
men that provides high sensitivity to identify early onset 
health deterioration, even before symptoms are perceived. 
Additionally, this parameter should be robust enough to 
allow large inter-individual differences, and it should 
be easy to assess. Additionally, we were interested in 
examining possible associations between depression, 
chronic stress, stressful life events and health status with 
the rate of change in declining steroid hormones.
RESULTS
Subject demographics and selected laboratory 
characteristics are summarized in Tables 1 and 2.
A principal components analysis for the ten salivary 
analytes was conducted. T, DHEA, E2, and P loaded on 
the same principal component. In order to represent the 
four sex steroids by a single indicator (i.e., through a linear 
combination of the four sex steroids) with the largest 
variance, a principal component analysis with one factor 
was conducted using only the four sex steroids - resulting 
in the principal component of declining steroid hormones 
(DSH) (see supplementary material Tables Xa and Xb). 
Zero-order correlations between age and salivary sex 
steroids revealed consistently negative associations (T: r 
= -.345,p < .000; DHEA: r = -.385, p < .000; E2: r = -.208, 
p < .000; P: r = -.276, p < .000). These results are in line 
with previous findings [13, 17, 18, 20]. Further correlation 
analysis revealed a negative association between age 
and DSH (DSH: r = -.416, p < .000, see Table Yb in the 
supplementary material). 
Quantile regressions of the single declining steroid 
hormones and the principal component of DSH as a linear 
function of age are represented in Figure 3. A mean annual 
reduction of 1.28% for T, of 3.52% for DHEA, of 1.18% 
for E2, and of 1.68% for P was calculated. DSH declined 
per additional year about .042 units, what reflects the mean 
rate of change in DSH.
To analyze moderation effects on the relationship 
between age and DSH, moderation analysis was conducted 
using two different regression techniques. Moderation 
analysis by OLS showed a significant association between 
age and DSH for depressive symptoms (ADS-L2: β = 
-.0017, p = .045), chronic stress (TICS: β = -.0010, p = 
.019), and perceived general health (GHQ: β = .0029, p = 
.035). Further moderation analyses by OLS failed to reach 
the level of statistical significance.
Moderation analysis by using robust regression 
showed significant associations between age and DSH 
for depressive symptoms (ADS-L2: β = -.0017, p = 
.033; Figure 4), chronic stress (TICS: β = -.0010, p = 
.015; Figure 4), and perceived general health (GHQ: β = 
.0029, p = .016; Figure 4). Further moderation analyses 
by robust regression failed to reach the level of statistical 
significance.
While the mean rate of change in DSH is .042, an 
increase of one standard deviation in depressive symptoms 
(ADS-L2) increases the rate of change in DSH to .053. 
For an increase of one standard deviation in chronic stress 
(TICS-2-K) the rate of change in DSH mounts from 
.042 to .056. For an increase of one standard deviation 
in general health (GHQ-12) the rate of change in DSH 
decreases from .042 to .028.
Moderation analysis and interaction plots for the 
association of the four sex steroids and age moderated 
by psychosocial factors are represented in supplementary 
material Table Z and Figure A-D.
DISCUSSION
This manuscript focuses on an integrated hormone 
parameter, namely the rate of change in declining steroid 
hormones, as an indicator of healthy aging in men.
The final sample consisted of 271 healthy men 
between the ages of 40 and 75 years, who provided 
psychometric data and saliva samples for hormone 
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Figure 1: Flow chart of the study procedure and participation
Figure 2: Timeline of the biological examination
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analysis. As expected, sex steroid hormones (T, DHEA, 
E2, and P) were strongly inter-correlated. A negative 
association with age was reported for all four of these sex 
steroids. An exploratory principal component analysis of 
all salivary hormones and immune parameters revealed 
strong evidence for a principal component consisting 
of the four sex steroids T, DHEA, E2, and P. In order to 
represent the four sex steroids by a single indicator with 
largest variance, we computed a principal component of 
declining steroid hormones (DSH) with T, DHEA, E2, 
and P. DSH was negatively associated with age. DSH 
decreased .042 units per additional year in the entire 
sample, while T or DHEA decreased 1.28% or 3.52% per 
year, respectively. The annual decline of DSH reflects the 
rate of change in declining steroid hormones. The rate of 
change in DSH is moderated by depressive symptoms, 
chronic stress, and general health - all to a small degree. 
More depressive symptoms and chronic stress seem to 
amplify age-related sex steroid decline, whereas better 
general health seems to buffer against age-related sex 
Figure 3: Association between age and the principal component of declining steroid hormones (DSH) and four sex 
steroids (T, DHEA, E2 and P) for different quantiles (red: lowest 10%; red and orange: lowest 25%; green: upper 
75%)
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steroid decline. Depressive symptoms and chronic stress 
increase the rate of change in DSH and better general 
health reduces it.
A continuous age-related decline in different sex 
steroid hormones in men has been reported consistently 
[17-20]. In this study, all four sex steroids were negatively 
associated with age, which agrees with much of the current 
literature. There is, however, also substantial conflicting 
literature [21]. Age-related decline of total T, DHEA, E2, 
or P in blood serum is more difficult to capture than free 
sex hormone levels because of an age-related increase in 
sex hormone binding globulin that additionally reduces 
free sex hormone levels (SHBG). Therefore, levels of free 
or bioavailable T, DHEA, E2, or P seem to decline more 
consistently [18, 30, 31], even though there is substantial 
conflicting literature [32]. Measurement of sex steroids in 
saliva, as opposed to in blood serum, has the advantages 
of directly quantifying the hormone in its unbound form, 
being a low invasive procedure and producing very low 
costs. 
Already in the 1980’s, Wang and colleagues or 
Vittek and colleagues have shown salivary hormone 
Figure 4: Moderation plots of the associations between age and the principal component of declining steroid hormones 
(DSH) by depressive symptoms (top left: ADS-L2; top right: BSI-18-D), chronic stress (middle left: TICS-2-K), 
stressful life events (middle right: SLE), and general health (bottom left: GHQ-12; bottom right: SF-36)
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measurements to be equivalent to blood hormone 
measurements [33, 34]. Gavrilova and Lindau found 
that the collection of salivary specimens in older men 
is feasible and they provide relevant information on 
conditions of aging [32]. The levels of salivary sex steroid 
hormones in this sample are similar to other samples of 
males aged 57 to 85 and reflect a typical age-related sex 
steroid decline, as compared to younger male samples [30, 
35].
Considerable interest is paid to T decline and its 
treatment in men while the decline of other relevant sex 
steroids is widely neglected [36]. Although widespread 
benefits have been reported for DHEA supplementation in 
men and a relevant contribution to sexual health and body 
composition in men has been shown for E2 11,13,26,37], 
free DHEA or E2 decline has not been sufficiently 
addressed [14]. Instead of neglecting this decline and 
focusing only on T decline, DHEA, E2, and P decline 
could be used to further strengthen an integrated parameter 
capturing aging processes in males. 
Different methodological and theoretical problems 
do arise when using only one hormonal parameter as 
an indicator of declining health in men [9, 10, 38]. A 
hormonal parameter involving information from different 
outcome measures is much more robust against bias 
than, for example, T alone. Furthermore, not the total 
amount of circulating sex steroids, but the rate of change 
in DSH, provides a sensitive parameter of the hormonal 
aging process in groups and, if measured repeatedly, 
in individuals. As a steeper decline of sex steroids 
is recognized as health compromising [17, 27], the 
information provided by this parameter can be used as the 
basis for future interventions addressing endocrine health 
in aging males.
Sex steroids are highly inter-correlated (see 
supplementary material Table Ya). Following others in 
the field, we conducted a principal component analysis 
of salivary analytes [39, 40]. Our analysis showed that 
the four sex steroids (T, DHEA, E2, and P) are loading 
strongly on the same principal component. Therefore, 
only these four sex steroids were included to compute the 
principal component of declining steroid hormones (DSH) 
reflecting only variance of these four sex steroids in DSH 
(see supplementary material Table Xb).
The negative association of DSH and age is 
moderated by psychosocial factors in healthy men. The 
relationship of depressive symptoms and sex steroids is 
discussed controversially within research. However, a 
great body of literature supports the perspective that higher 
levels of T, DHEA, and E2 in older men are negatively 
associated with depression [9, 41-44]. For P, studies in post 
menopausal women indicate that decreased P levels are a 
risk factor for depression [45]. In men, decreased plasma P 
levels have been found during a major depressive episode, 
but the sample size of the study is too small to draw final 
conclusions [46. Visual analysis of the interaction plots for 
two depression measurements (ADS-L2 and BSI-18-D) 
show consistently higher levels of depressive symptoms 
associated with a steeper age-related decline of T, DHEA, 
E2, P, and DSH. The fact that in our study moderation 
Figure 5: A model of successful aging: Biological aging as main contributor of successful aging. Endocrine health, 
operationalized by the rate of change in DSH, reflects within biological aging a possible target to decelerate biological aging via lifestyle 
factors, psychological support or hormone replacement.
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analysis revealed significant effects for the association of 
age and DSH moderated by ADS-L2 but not by BSI-18-D, 
might be due to the precision of depression measurement 
of the two instruments. While ADS-L2 consists of 20 
items and reflects a broader spectrum of depression 
measurement, BSI-18-D consists of only 6 items and is 
generally considered a brief screening tool.
Chronic stress and stressful life events are 
considered to attenuate sex steroid secretion [47]. For 
different sex steroids, a stress reducing effect is discussed 
for males [48]. In our study, more chronic stress measured 
with the TICS-2-K revealed an amplifying effect on the 
negative association between DSH and age. The two-item 
factor of stressful life events (amount and quality) failed 
to significantly moderate this association. These results 
concur with previous work indicating that chronic stress 
negatively influences healthy aging and contributes to 
health deterioration reflected by biological markers [49].
A steeper sex steroid decline with age is considered 
health compromising [27], while better general health 
decelerates age-related sex steroid decline [17, 28]. 
Our results further support this finding. The negative 
association between age and DSH is significantly buffered 
by better general health measured with the GHQ-12. 
Visual analysis of the interaction plot shows the same 
tendency for general health measured with the SF-36, but 
it fails to become significant in the moderation analysis. 
By contrast, neither a significant moderation effect nor 
a visual detectable trend has been observed for AMS. 
This might be due to the fact that the AMS measures 
17 perceived symptoms related to an advanced aging 
process and androgen dysfunction. In our study, only self-
reporting healthy men were included causing perhaps too 
little variance in the AMS.
Taken together, the new parameter DSH has been 
validated by these well-studied constructs in our sample of 
healthy men. As shown in Figure 5, our results lend further 
evidence for a model of healthy and successful aging. Life 
style factors, psychological factors, and general health, as 
well as hormone replacement, promote endocrine health 
and, therefore, help to maintain successful aging in men.
There are several limitations that need to be 
considered when interpreting our results. One major 
limitation of this study is its cross-sectional design; causal 
inferences are not allowed. The hormonal differences 
in relation to age are between-subject effects and they 
need to be further examined in relation to hormonal 
changes over time. Therefore, longitudinal data are 
required to replicate our between-subject results and to 
further confirm these in a within-subject design. Another 
limitation, albeit an intentional one, is that the results 
only apply to men reporting being in a good health state. 
The generalizability of our results is restricted to self-
reporting healthy men between the ages 40 and 75. Group 
comparisons between self-reporting healthy men and 
men with a well defined clinical syndrome are needed to 
confirm the discriminant validity of the new parameter. 
Our data indicate that a higher rate of change in DSH 
is related to higher morbidity and to more age-related 
disorders. A methodological limitation of the study is 
the single assessment of the salivary parameters. Steroid 
hormones tend to show variance between consecutive 
days. Therefore, repeated measurements on different days 
and subsequent calculation of a mean for each hormonal 
parameter would provide higher reliability. Additionally, 
the psychometric data were measured one to three weeks 
before saliva samples were obtained. This time gap might 
have resulted in a considerable bias between psychometric 
and biological outcomes, however measured psychometric 
constructs reflect traits rather than states.
In conclusion, the annual decline of DSH, namely 
the rate of change in declining steroid hormones, has 
been shown to be a promising parameter for monitoring 
healthy aging in men. In addition to the measurement 
of the total amount of single sex steroids, which vary 
greatly from individual to individual, the rate of change in 
declining steroid hormones provides a more robust picture 
of a male’s endocrine state. Sex steroid reference ranges 
might help to initially integrate the hormonal situation of 
a single male into a context, but repeated measurements 
over a longer time period, and the monitoring of the rate 
of change in DSH, would provide a more sophisticated 
picture of endocrine aging processes and of possible 
health deterioration. As shown in Figure 5, monitoring 
the rate of change in DSH enables the development of 
a timely and effective strategy to maintain endocrine 
health through eventual psychological interventions, 
life-style interventions or hormone supplementation. 
Hormonal changes occur usually long before symptoms 
are perceived and disorders are established. In order to 
effectively prolong the span of good health in men, this 
new integrated parameter allows for action before health 
damage has become an irreversible reality.
MATERIALS AND METHODS
Participants
Two hundred seventy-one men between the ages 
40 and 75 years (Mage = 57.06; SDage = 10.68) provided 
both psychometric and biological data in the study Men’s 
Health 40+. Subjects were recruited through web pages 
and flyers. Further inclusion criteria for the study, were 
good knowledge of German and being healthy (not having 
any acute medical or psychiatric disorder). The health 
state was controlled by a health question from the first 
psychometric test battery “How would you describe your 
current health condition?” with the response options from 
“very bad” to “very good”. 
Table 1 shows the sample characteristics including 
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age, current health condition, body mass index (BMI), 
education according to the International Standard 
Classification of Education [50], smoking status, 
medication intake and medication type.
The study protocol was approved by the local 
ethics committee of the University of Zurich. All subjects 
provided written informed consent.
Procedure
The participants processed psychometric test 
batteries 1 to 3 (PTB1-3) independently online for 
three consecutive weeks. 271 participants attended the 
biological examination in the fourth week. Examination 
sessions took place individually or in groups of maximum 
three participants and lasted approximately one hour and 
fifteen minutes. Figure 1 shows a flow chart of the study 
procedure and participation.
The day of the biological examination the 
participants were fasting overnight. Upon arrival, 
the participants were instructed about the following 
procedures and a short activity screening was performed. 
Standardized saliva sampling started at 8:00am to control 
for diurnal variation of hormone secretion. Subsequently, 
body measures, such as height, weight, body cell and 
fat mass, or cardiovascular parameters were measured 
according to the standardized test procedure between 
8:30am and 9:15am (see Figure 2).
Psychometric Tests
Depressive symptoms
Aging has been shown to be accompanied by an 
increase in mild to moderate depressive symptomatology 
[1]. Furthermore, not only steroid hormones [51-53], 
but also markers of inflammation have been shown to 
be reciprocally related to depressive symptoms [54]. 
Therefore, we used the depression scale Allgemeine 
Depressionsskala-Langform 2 (ADS-L2) to assess 
participants’ depressive symptomatology [55]. As the 
ADS-L2 is based on the CES-D scale, which is a self-
report depression scale for research in the general 
population [56], it was well suited for this non-clinical 
sample. We also used the depression subscale of the Brief 
Symptom Inventory-18 (BSI-18-D) to obtain an additional 
score for depression [57].
Chronic stress and stressful life events
As chronic stress reflects a major health concern and 
contributes to the etiology of several age-related disorders 
such as cardiovascular disease or Alzheimer’s disease [58-
60], it serves as well studied risk factor for dysfunctional 
aging-patterns. Chronic stress has been shown to be related 
to decreased sex steroid secretion or elevated cortisol 
levels as well as elevated inflammation [61, 62]. Chronic 
stress was assessed through the multidimensional Trier 
Inventar zur Erfassung von chronischem Stress - Version 2 
- Kurzversion (TICS-2-K), which asks participants on the 
frequency of stressful situations in the last 3 months [63]. 
Stressful life events (SLE) are discussed to play a specific 
role in precipitating both mental and somatic disorders 
[64]. Since the amount of SLE increases as a function of 
age, it is assumed to contribute to the pathophysiology 
of non-healthy aging. As people differ in frequency 
and intensity of experienced stressful life events, we 
assessed the amount of experienced stressful life events 
and discriminated 8 categories with two self-rate items. 
Participants were asked “How many stressful life events 
have you experienced?” with response options from 0 to 
6 and 7 or more. Subsequently, a list of 8 dimensions of 
stressful life events was presented, where more response 
options were possible to choose (e.g. death of a loved one, 
serious illness, poverty in childhood, or physical abuse in 
childhood). Following Sali and colleagues the amount and 
the weighted quality of stressful life events were computed 
to a total score (SLE-S) [65].
General health
To assess the participants’ general health state, 3 
different measures (GHQ-12, SF-36 and AMS) were 
used. The General Health Questionnaire-12 (GHQ-12) 
measures general psychological health and was primarily 
conceptualized to be used in the general population [66-
68]. The Short Form-36 (SF36) is a multidimensional 
self-report questionnaire measuring a total score of 
general health [69]. The Aging Males’ Symptoms scale 
(AMS) assesses age-related symptoms such as excessive 
sweating, irritability, or less morning erections [70]. 
Endocrine parameters
Saliva samples were obtained in a standardized 
procedure between 8:00am and 8:15am. Participants 
were asked to fill subsequently 3 salicaps of 2ml capacity 
(SaliCaps, IBL International GmbH, Hamburg, Germany) 
with saliva. Out of each sample 10 parameters were 
analyzed (testosterone (T), dehydroepiandrosterone 
(DHEA), estradiol (E2), progesterone (P), melationin 
(M), cortisol (C), alpha-amylase (AA), C-reactive protein 
(CRP), interleukin-6 (IL-6), and immune globulin A (IgA); 
for descriptive statistics of sex steroids see table 2).
All saliva samples were stored at −20◦C until 
required for biochemical analysis. T, E2, P, C, and AA 
were analyzed in the biochemical laboratory of the 
Department of Psychology of the University of Zurich, 
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while DHEA, M, IL-6, CRP, and IgA were analyzed in 
the biochemical laboratory of the Technical University of 
Dresden.
Potential covariates and confounders
Covariates included were fat mass and muscle 
mass measured with the bioelectrical impedance analysis 
(BIACORPUS RX 4000; BodyComp V 8.5) [11, 29, 71], 
blood pressure and pulse measured with a blood pressure 
monitor (Medisana MTX USB 51083) [72], smoking 
status, alcohol consumption [29, 73], medication intake 
[74, 75], drug consumption [76], and amount of potency 
medicine or related drug consumption [77]. Also included 
as covariates were having had a cold or other disease 
during the last two weeks [78, 79], having had an injury 
or bleeding in the mouth in the last days [80], having 
been physically active within the last 24 hours [73, 81]. 
To address participants’ delay the exact starting time of 
saliva collection was used as a covariate [82]. Waking time 
of the day of the biological examination [83], the general 
sleep quality (PSQI) [16, 84], education [85], income [85], 
and neuroticism (BFI-K) [86], as well as time being in a 
relationship [87], and amount of children [88] were further 
included as covariates.
Statistical analysis
First, outliers were identified and removed for the 
salivary parameters. Values that were greater or less than 
three standard deviations around the mean were removed 
[89]. For T 1.1% (n = 3), for DHEA 1.8% (n = 5), for 
E2 0.4% (n = 1), and for P 2.6% (n = 7) of values were 
removed.
In order to reduce dimensionality of the ten 
outcome variables, we subsequently calculated a principal 
component analysis with all salivary parameters using 
varimax rotation and four factors [90]. According to the 
factor loadings, the four sex steroid hormones (T, DHEA, 
E2, and P) mainly loaded on the first principal component. 
Therefore, a second principal component analysis was 
conducted only with the four sex steroids computing one 
principal component - principal component of declining 
steroid hormones (DSH). DSH with 256 observations 
included was used for further analysis. Subsequently, we 
computed zero-order correlations between age and salivary 
sex steroids and DSH (Spearman’s rho, one-tailed). 
To assess the rate of change in declining steroid 
hormones for different risk groups of the population, 
quantile regressions were performed on DSH as well as 
the sex steroid hormones T, DHEA, E2, and P as a linear 
function of age (see Figure 3). Quantile regressions 
were computed for the 10%- and the 25%-quantile of 
the sample. To illustrate the risk groups of low levels of 
sex steroids, the areas between the regression lines were 
colored red (0 - 10%), orange (10 - 25%), and green (25 
- 100%).
In a next step, we conducted separate moderation 
analyses for the relation between age and DSH moderated 
by depressive symptoms, chronic stress, stressful life 
events, and general health. Additionally, the potential 
covariates and confounders introduced before were 
included for the analyses. A comprehensive residual 
analysis was conducted for each model, in which 
we identified three relatively influential data points. 
Therefore, two solutions were calculated. The first solution 
was performed through ordinary least squares (OLS) 
regressions. The second solution was performed using 
robust regression, which put lower weights on extreme 
data points to reduce their influence on parameter and 
standard error estimates [91].
All analyses were conducted using R version 
3.2.2. [92]. Quantile regressions were performed with 
the R-Package “quantreg” and robust regression with the 
R-Package “robustbase” using the settings suggested by 
Koller and Stahel [93]. Level of significance was chosen 
at α = 0.05.
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